Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...

This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.

BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal ...

Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors ...

Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor ...

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...

Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...

The external assessment group (EAG) did a systematic review to identify evidence on the clinical effectiveness and diagnostic accuracy of IHC- and MSI-based testing strategies for detecting Lynch ...